Serum testosterone concentrations and testosterone medications

Published: 27 March 2023| Version 1 | DOI: 10.17632/nvc843m5tx.1
, Matthew Krasowski


Supplementary_file: Data for total serum testosterone measurements performed at the University of Iowa Hospitals and Clinics from May 1, 2009 to March 31, 2022 along with whether patient was taking testosterone medication at time of serum measurement. The data elements include: deidentified patient number, legal sex in the electronic medical record, gender identity in electronic medical record (if available), sex assigned at birth in electronic medical record (if available), patient in years at time of serum testosterone measurement (greater than 89 years expressed as ">89"), deidentified order number for the testosterone lab measurement, total serum testosterone concentration (ng/dL), category for the serum testosterone concentration, location type (outpatient or inpatient) for when serum testosterone measurement was made, methodology for serum testosterone measurement (immunoassay or mass spectrometry), testosterone medication prescription at time of serum testosterone measurement (yes or no), route of administration for testosterone medication (if applicable), specific testosterone medication and dose (if applicable; in some cases dose was unknown).


Steps to reproduce

This study was conducted with ethical approval from the University of Iowa Institutional Review Board as a retrospective study with waiver of informed consent. We utilized electronic medical record reporting tools (Epic Reporting Workbench) to retrieve all serum testosterone measurements from May 1, 2009 to March 31, 2022 along with pharmacy medical records for any testosterone preparations prescribed to patients who had serum testosterone measurements [1]. During this timeframe, the majority of serum testosterone measurements were performed at the University of Iowa Hospitals and Clinics core clinical laboratory by immunoassay using the Roche Diagnostics Elecsys® Testosterone II assay on either Modular E170 (2009-2012) or cobas e602 analyzers (2013-present). The analytical measurement range (AMR) and clinical reportable range (CRR) are 12 - 1500 ng/dL (0.4 -52.1 nmol/L). Total imprecision is less than 6.0%. Some serum testosterone measurements (especially those ordered for children or female patients who generally have lower serum testosterone concentrations) were sent to commercial reference laboratory which analyzed by liquid chromatography/tandem mass spectrometry (LC/MS/MS). Some patients had measurements performed by both methodologies at various times. Reference: [1] M.D. Krasowski, B.A. Ford, J.S. Klutts, C.S. Jensen, A.S. Briggs, R.A. Robinson, L.A. Bruch, N.J. Karandikar, Using Focused Laboratory Management and Quality Improvement Projects to Enhance Resident Training and Foster Scholarship, Acad Pathol 4 (2017) 2374289517722152.


University of Iowa


Medical Laboratory Technology, Immunoassay, Testosterone, Liquid Chromatography Mass Spectrometry